A Study of ABT-751 in Patients With Renal Cell Cancer

Abbott

Status and phase: Completed; Phase 2

Conditions: Renal Cell Cancer

Treatments: Drug: ABT-751

Study type: Interventional

Funder types: Industry

Identifiers

NCT00073112

M02-416

Details and patient eligibility

About

The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with renal cell cancer. Patients will receive ABT-751 by mouth daily for 21 days. Patients will be off drug for 7 days before starting the next cycle of drug.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

• Renal Cell Carcinoma.
• Recurrent tumor.
• At least 6 weeks post-nephrectomy.
• Able to tolerate normal activities of daily living.
• Adequate bone marrow, kidney, and liver function.

Exclusion Criteria

• Pregnant or breast feeding.
• Anti-tumor therapy within 4 weeks of the start of ABT-751 administration.
• CNS metastasis.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)